GENFIT (GNFT.PA)

FR0004163111 - Common Stock

4.2  0 (0%)

Fundamental Rating

4

Taking everything into account, GNFT scores 4 out of 10 in our fundamental rating. GNFT was compared to 74 industry peers in the Biotechnology industry. GNFT may be in some trouble as it scores bad on both profitability and health. GNFT is growing strongly while it is still valued neutral. This is a good combination!



2

1. Profitability

1.1 Basic Checks

GNFT had negative earnings in the past year.
GNFT had a negative operating cash flow in the past year.
GNFT had negative earnings in 4 of the past 5 years.
In the past 5 years GNFT reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of GNFT (-16.62%) is better than 70.00% of its industry peers.
The Return On Equity of GNFT (-42.52%) is better than 61.43% of its industry peers.
Industry RankSector Rank
ROA -16.62%
ROE -42.52%
ROIC N/A
ROA(3y)-1.25%
ROA(5y)-15.15%
ROE(3y)-3.71%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 94.32%, GNFT belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
GNFT's Gross Margin has improved in the last couple of years.
GNFT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.81%
GM growth 5Y4.62%

3

2. Health

2.1 Basic Checks

GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GNFT remains at a similar level compared to 1 year ago.
The number of shares outstanding for GNFT has been increased compared to 5 years ago.
Compared to 1 year ago, GNFT has a worse debt to assets ratio.

2.2 Solvency

GNFT has an Altman-Z score of -1.72. This is a bad value and indicates that GNFT is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.72, GNFT is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.92 indicates that GNFT is somewhat dependend on debt financing.
GNFT has a Debt to Equity ratio of 0.92. This is comparable to the rest of the industry: GNFT outperforms 42.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF N/A
Altman-Z -1.72
ROIC/WACCN/A
WACC7.43%

2.3 Liquidity

GNFT has a Current Ratio of 2.94. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of GNFT (2.94) is better than 65.71% of its industry peers.
A Quick Ratio of 2.94 indicates that GNFT has no problem at all paying its short term obligations.
GNFT has a Quick ratio of 2.94. This is in the better half of the industry: GNFT outperforms 65.71% of its industry peers.
Industry RankSector Rank
Current Ratio 2.94
Quick Ratio 2.94

7

3. Growth

3.1 Past

The earnings per share for GNFT have decreased strongly by -21.75% in the last year.
GNFT shows a strong growth in Revenue. In the last year, the Revenue has grown by 43.70%.
GNFT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.49% yearly.
EPS 1Y (TTM)-21.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.74%
Revenue 1Y (TTM)43.7%
Revenue growth 3Y70.09%
Revenue growth 5Y38.49%
Sales Q2Q%18.81%

3.2 Future

GNFT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.37% yearly.
Based on estimates for the next years, GNFT will show a very strong growth in Revenue. The Revenue will grow by 27.66% on average per year.
EPS Next Y303.9%
EPS Next 2Y-73.62%
EPS Next 3Y44.37%
EPS Next 5YN/A
Revenue Next Year67.79%
Revenue Next 2Y-11.44%
Revenue Next 3Y-0.49%
Revenue Next 5Y27.66%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GNFT. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 12.74, which indicates a correct valuation of GNFT.
Compared to the rest of the industry, the Price/Forward Earnings ratio of GNFT indicates a rather cheap valuation: GNFT is cheaper than 85.71% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.94, GNFT is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 12.74

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

GNFT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as GNFT's earnings are expected to grow with 44.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-73.62%
EPS Next 3Y44.37%

0

5. Dividend

5.1 Amount

GNFT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

GENFIT

EPA:GNFT (7/17/2024, 11:36:25 AM)

4.2

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap209.42M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 12.74
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.62%
ROE -42.52%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 94.32%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.92
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.94
Quick Ratio 2.94
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-21.75%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y303.9%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)43.7%
Revenue growth 3Y70.09%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y